Maxim Group Initiates Coverage On 20/20 Biolabs with Buy Rating, Announces Price Target of $5

Benzinga Newsdesk www.benzinga.com Neutral 59.6%

Neg 0% Neu 59.6% Pos 0%

Maxim Group analyst Michael Okunewitch initiates coverage on 20/20 Biolabs (NASDAQ:AIDX) with a Buy rating and announces Price Target of $5.